#USA #New York #Faruqi & Faruqi #Josh Wilson #Baxter International

Urgent Notice for Baxter Investors

As the deadline for investor action approaches, Faruqi & Faruqi, LLP calls upon those who suffered losses from their investments in Baxter International, Inc. to take immediate steps. With a major federal securities class action looming, it's vital for affected shareholders to understand their legal rights and options.

Background of the Investigation

Faruqi & Faruqi, LLP, a highly regarded national securities law firm, has begun investigating potential claims against Baxter International relating to significant allegations against the company. Investors who purchased Baxter securities from February 23, 2022, to July 30, 2025, are particularly encouraged to reach out. The critical deadline to seek the role of lead plaintiff in the pending class action is set for December 15, 2025.

Allegations Against Baxter International

The core of the investigation hinges on serious allegations that Baxter and its executives may have violated federal securities laws. Specific claims being investigated include:

• - Misleading statements regarding the Novum LVP medical device, which purportedly faced systemic defects leading to malfunctions such as underinfusion, overinfusion, and even complete failure to deliver necessary fluids.
• - Failure to disclose that Baxter was aware of multiple incidents resulting in patient injury or death due to these device malfunctions.
• - Inadequate responses from Baxter regarding persistent design flaws, which were reportedly highlighted in customer alerts that did not effectively resolve ongoing issues.
• - A raised risk indicating that Baxter may have needed to withdraw existing Novum LVPs from service and halt all new sales of these devices.

Impact of the Allegations

These allegations culminated in a significant market reaction. On July 31, 2025, when Baxter announced a voluntary pause on shipments and installations of the affected devices, its stock price dropped by 22.4%, closing at $21.76 by day’s end. This plunge underscores the severe impact that these fraudulent misrepresentations may have had on investors’ portfolios.

The Role of Lead Plaintiff

Under securities class action laws, a lead plaintiff is appointed to manage the litigation on behalf of the rest of the class members. This individual is typically someone who holds the largest financial stake in the outcome of the lawsuit and whose experiences are typical of all members. The lead plaintiff’s decisions will direct the progress of the case. However, any member of the affected group can choose to either pursue the position of lead plaintiff with the counsel of their choice or remain an absent class member and still retain their rights to any potential recovery.

Encouragement to Act

Faruqi & Faruqi, LLP encourages any investors who have information about Baxter's conduct, including whistleblowers or former employees, to come forward. If you believe you have been adversely affected by your investment in Baxter International, now is the time to act.

Contact Information

To engage in discussions about your legal rights, or to simply gather more information regarding the Baxter International class action, you can reach out directly to James (Josh) Wilson, a partner at Faruqi & Faruqi, LLP. He can be contacted through the following:

• - Phone: 877-247-4292 or 212-983-9330 (Ext. 1310)
• - Visit: Faruqi & Faruqi, LLP

Conclusion

As the December 15 deadline nears, investors should not delay in seeking legal counsel. It’s crucial to remain informed and take swift action to protect your rights as an investor in Baxter International.